11th Microbiome Movement USA Summit 2026
Translating Advanced Microbiome Science into Clinical and Commercial Impact, to Build Investor Confidence and Deliver Safe, Effective Solutions for End Consumers.
Momentum is returning to microbiome-based therapies. Companies like Vedanta Biosciences, Siolta Therapeutics, Microbiotica and Seres Therapeutics are moving closer to commercialisation across C. diff, oncology and immune-related diseases. Recent financings, including mbiomics (鈧�30M), Kanvas Biosciences ($48M) and EnteroBiotix (拢19M), alongside the Gates Foundation鈥檚 $2.5 billion commitment to women鈥檚 health, signal growing confidence in the field.
But momentum alone isn鈥檛 enough. Unclear mechanisms, inconsistent clinical efficacy, and limited pharma and investor trust still stand between promising science and real-world patient impact.
That鈥檚 why the 11th Microbiome Movement USA Summit returns to Boston this November. You will join C-suite, VP and Director-level leaders across pioneering biopharma, regulators, and both microbiome-curious and first-time investors to answer one critical question:
How do you translate microbiome biology into clinically validated, commercially viable therapies to effectively treat your indication of interest?
Don鈥檛 miss networking opportunities and insights from Ferring Pharmaceuticals, Nestl茅 Health Science, Vedanta Biosciences, MRM Health, Seventure Partners, The Gates Foundation, and more, as you discover how to demonstrate robust clinical efficacy, rebuild stakeholder confidence, and position your program for regulatory and commercial success.
听
听
Date and Time: Mon, 09 Nov 2026 08:00 - Wed, 11 Nov 2026 18:00
Event details
The Colonnade Hotel
The Colonnade Hotel, 120 Huntington Avenue, Boston, 02116, United States